New Kit Identifies Endonuclease Impurities

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-02-2019
Volume 43
Issue 5
Pages: 12

The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.

The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.

Cygnus Technologies

Recent Videos
Jay Rajagopalan, senior director—Engineering & Product Management for Malema at PSG Biotech